AHA 2021 This remote hypertension and LDL-c management program enrolled over 10,000 patients at high CV risk. The program effectively improved hypertension and LDL-c control across a diverse health care network.

AHA 2021 This analysis of the EMPEROR-Preserved trail showed that empagliflozin reduced the primary endpoint of time to first event of CV death or HF hospitalization by 17%, compared to placebo, in HF patients with LVEF ≥50%.

AHA 2021 Using data of the ASCEND trial, this study showed that there was no significant effect of aspirin on dementia outcomes compared to placebo in patients with T2DM.

AHA 2021 In the I-STOP AF trial, n-of-1 trials with individual triggers did not result in a change in AF-related quality of life compared to monitoring only.

AHA 2021 The CHIEF-HF study showed that canagliflozin improved symptoms in HF as measured by KCCQ-TSS. The benefits with canagliflozin were observed as early as 2 weeks and sustained until the end of treatment at 3 months.

AHA 2021 The PREPARE IT-2 trial enrolled non-hospitalized COVID-19 patients and showed that icosapent ethyl did not reduce COVID-19-related hospitalization or death compared to placebo after 28 days.

AHA 2021 A novel software algorithm with input of irregular heart rhythm detection by Fitbit wearables had a positive predictive value of 98% for undiagnosed atrial fibrillation (AF).

AHA 2021 The majority of cognitive outcome tests was not different between AF patients treated with dabigatran or warfarin after two years in the GIRAF trial.

AHA 2021 This randomized trial assessed the acute physiologic consequences of coffee consumption and found that drinking coffee did not increase atrial arrhythmias but did result in more PVCs, less sleep and more physical activity.

AHA 2021 In a cluster trial of villages, BP control was significantly improved by a village doctor-led intervention for hypertension treatment compared to usual care among hypertensive residents in rural China.

This study assessed the association between objectively measured sleep onset and risk for developing CVD in a large cohort and found a U-shaped relationship between sleep onset time and CVD incidence.

The SGLT2 inhibitor dapagliflozin reduced albuminuria compared to placebo in CKD patients with and without T2DM in the DAPA-CKD trial, with a more pronounced effect in patients with T2DM.